Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
55
Drug Approvals
EXELON 9.5MG-24H TRANSDERMAL PATCHES
- Approval Date
- Jul 18, 2025
- Company
- lts lohmann therapie-systeme
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (1017 trials with phase data)• Click on a phase to view related trials
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 435
- Registration Number
- NCT06705504
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42494
- Registration Number
- NCT06671314
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 376
- Registration Number
- NCT06662825
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1665
- Registration Number
- NCT06662812
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3632
- Registration Number
- NCT06644638
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 143
- Next
News
Livzon's Dual-Target IL-17A/F Antibody LZM012 Outperforms Secukinumab in Phase III Psoriasis Trial
Livzon Pharmaceutical's LZM012, the first domestic dual-target IL-17A/F monoclonal antibody, achieved superior efficacy compared to Secukinumab in a Phase III trial for moderate to severe plaque psoriasis.
Synendos Therapeutics Names Dr. George Garibaldi as CMO to Lead Phase 2 Development of Novel Neuropsychiatric Therapy
Synendos Therapeutics has appointed Dr. George Garibaldi as Chief Medical Officer as the company transitions from Phase 1 to Phase 2 clinical development of its lead drug candidate SYT-510.
Uniquity Bio Appoints Will Kane as CEO to Lead Anti-TSLP Therapy Through Phase III Development
Uniquity Bio has appointed Will Kane as President and CEO to advance solrikitug, a monoclonal antibody targeting TSLP, through completion of three Phase II trials and preparation for Phase III development.
Novartis Secures Canadian Public Reimbursement for Cosentyx in Hidradenitis Suppurativa
Novartis successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa.
Renasant Bio Raises $54.5M to Develop Novel Ion Channel Therapies for ADPKD
Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).
Novartis Secures Exclusive Option for Sironax's Blood-Brain Barrier Platform in $175M Deal
Sironax has granted Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier crossing technology designed to enhance brain delivery of therapeutics.
STAMPEDE Trial Shows Metformin Improves Metabolic Health in Metastatic Prostate Cancer Patients Despite No Survival Benefit
The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15).
Novartis Receives Approval for First Malaria Treatment Designed for Newborns and Young Infants
Novartis has received Swiss regulatory approval for Coartem Baby, the first malaria treatment specifically formulated for newborns and infants weighing 2-5 kilograms.
Ascentage Pharma Strengthens Leadership Team with New CFO and Senior VP Appointments
Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.
FDA Approves First Xolair Biosimilar Omlyclo for Allergic Diseases, Marking Milestone in Allergy Treatment Access
The FDA has approved Omlyclo (omalizumab-igec) as the first biosimilar interchangeable with Xolair for treating allergic asthma, chronic rhinosinusitis with nasal polyps, chronic urticaria, and food allergies.